Browse Drug Recalls
201 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 201 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 201 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jul 17, 2015 | lidocaine HCl, 1%, 30 mg per 3 mL, 3 mL Total Volume in a syringe, Rx only, P... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 2%, Preservative Free, Total Volume 2mL, Product code 2R3323, ... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | HYDROmorphone HCl, 0.5 mg per mL in 0.9% Sodium Chloride, 1 mL Total Volume i... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | methadone HCl, 10 mg per mL, 1 mL Total Volume in a syringe, For IV Use Only,... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 1%, in 0.9% Sodium Chloride, Preservative Free, Total Volume 1... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | remifentanil HCl, 50 mcg per mL, 100 mcg per 2 mL, in 0.9% Sodium Chloride, P... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 0.5%, 5 mg per mL, in 0.9% Sodium Chloride, 1 mL Total Volume ... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | labetalol HCl, 5 mg per mL, 20 mg per 4 mL, 4 mL total Volume in a syringe, F... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | fentaNYL Citrate, 25 mcg per mL in 0.9% Sodium chloride, 1 mL Total Volume in... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | neostigmine Methylsulfate, 1 mg per mL, 2 mg per 2 mL, 2 mL Total Volume in a... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | Fentanyl Citrate 16.67 mcg per mL and Bupivacaine HCl 0.1667% in 0.9% Sodium ... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 2%, 20 mg per mL (100 mg per 5 mL), 5 mL Total Volume in a syr... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | morphine Sulfate, 0.5 mg per mL, in 0.9% Sodium Chloride, Preservative Free (... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | morphine Sulfate, 1 mg per mL (2 mg per 2 mL), in 0.9% Sodium Chloride, Prese... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | midazolam HCl, 1 mg per mL (2 mg per 2 mL), in 0.9% Sodium Chloride, 2 mL Tot... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | morphine Sulfate, 0.5 mg per mL, in 0.9% Sodium Chloride, Preservative Free, ... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | Buffered Lidocaine, 1%, In Sodium Bicarbonate 8.4%, 1 mL Total Volume in a sy... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 1%, 10 mg per 1 mL, 1 mL Total Volume in a syringe, Rx only, P... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | glycopyrrolate, 0.2 mg per mL, 0.6 mg per 3 mL, 3 mL Total Volume in a syring... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 1%, 10 mg per mL (50 mg per 5 mL), 5 mL Total Volume in a syri... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | midazolam HCl, 1 mg per mL, in 0.9% Sodium Chloride, 1 mL Total Volume in a s... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | succinylcholine Chloride Injection, 20 mg per mL, 100 mg per 5 mL, 5 mL Total... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | fentaNYL Citrate, 5 mcg per mL, 15 mcg per 3mL, in 0.9% Sodium chloride, 3 mL... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | fentaNYL Citrate, 10 mcg per 1 mL, in 0.9% Sodium Chloride, Preservative Free... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | lidocaine HCl, 2%, 20 mg per mL (60 mg per 3 mL), 3 mL Total Volume, Product ... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | morphine Sulfate, 2 mg per mL, in 0.9% Sodium Chloride, 1 mL Total Volume in ... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | rocuronium Bromide, 10 mg per mL, 50 mg per 5 mL, Preservative Free, 5 mL Tot... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | HYDROmorphone HCl, 1 mg per mL, in 0.9% Sodium Chloride, 1 mL Total Volume in... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | ketamine HCl, 10 mg per mL, 50 mg per 5 mL, in 0.9% Sodium Chloride, 5 mL Tot... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Jul 17, 2015 | morphine Sulfate, 1 mg per mL (2 mg per 2 mL), in 0.9% Sodium Chloride, Prese... | Stability Data Does Not Support Expiry: potential loss of potency in drugs packaged and stored in... | Class II | Pharmedium Services, LLC |
| Apr 20, 2015 | IC-GREEN (indocyanine green for injection, USP), 25 mg Kit (NDC 17478-701-02,... | Subpotent Drug: Low out-of-specification potency result of the drug product. | Class III | Akorn, Inc. |
| Apr 2, 2015 | Acarbose Tablets 50 mg a)10 x 10 Unit Dose Tablets per Blister Pack, b)100 co... | Subpotent Drug: The firm received an out of specification result for Assay (potency was below spe... | Class II | Boehringer Ingelheim Roxane Inc |
| Oct 30, 2014 | Heparin Sodium in 0.9% Sodium Chloride Injection, 1000 USP Heparin Units, 500... | Subpotent Drug: Heparin raw material was found to have low potency | Class II | Baxter Healthcare Corp. |
| Oct 2, 2014 | VERSAPHARM INCORPORATED Ethambutol Hydrochloride Tablets, USP, 100 mg, 100-co... | Subpotency: Out of Specification (OOS) result at the 36 month routine stability time point. | Class II | West-Ward Pharmaceutical Corp. |
| Apr 29, 2014 | Red Yeast Rice High Potency Dietary Supplement, 600 mg, packaged in a) 120-co... | Marketed Without An Approved NDA/ANDA: Product is being recalled due to excessive levels of lovas... | Class II | Independent Nutrition Center, Inc. |
| Feb 7, 2014 | Gelnique (oxybutynin chloride) Gel 10%, 100 mg in 1 g sachet, for topical use... | Subpotent Drug: Drug potency was compromised during shipment. | Class III | Actavis |
| Nov 4, 2013 | Hydravax High Potency Diuretic Weight Loss Solution, Pharmaceutical Grade, 45... | Marketed Without an Approved NDA/ANDA; this product is being recalled for containing an undeclare... | Class I | IQ Formulations, LLC |
| Oct 21, 2013 | Human Chorionic Gonadotropin, EP (HCG) in 5 mu. 2 mu, and 1 mu packages, For ... | Labeling: Label Error on Declared Strength; Firm states that erroneous potency information was fo... | Class I | Medisca Inc. |
| Aug 14, 2013 | 72HP MAXIMUM POTENCY MALE SEXUAL ENHANCEMENT, Dietary Supplement, supplied in... | Marketed without an Approved NDA/ANDA: products were found to contain undeclared sildenafil | Class I | Fabscout Entertainment, Inc |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.